Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
MAIA Biotechnology, Inc. Common Stock
(NY:
MAIA
)
1.870
UNCHANGED
Official Closing Price
Updated: 8:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MAIA Biotechnology, Inc. Common Stock
< Previous
1
2
3
4
Next >
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
February 04, 2025
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Present at Biotech Showcase 2025
January 10, 2025
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
January 07, 2025
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
December 19, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
December 16, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Private Placement of Approximately $950,000
December 09, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
December 03, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
November 07, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
November 05, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces $2.44 Million Private Placement
October 28, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
October 15, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer
September 10, 2024
From
MAIA Biotechnology
Via
Business Wire
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology (MAIA) is one of the earliest pioneers of telomere targeting as a therapeutic strategy
July 23, 2024
Via
AB Newswire
Exposures
Product Safety
MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
July 23, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
July 09, 2024
Via
AB Newswire
Exposures
COVID-19
Product Safety
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
June 07, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
June 07, 2024
Via
AB Newswire
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
June 06, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
June 06, 2024
Via
AB Newswire
MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
June 04, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology (MAIA) to Showcase Groundbreaking Telomere-Targeting Cancer Treatments at BIO International Convention 2024
June 04, 2024
Via
AB Newswire
MAIA Biotechnology Inc (MAIA) Stock Surges as Company Prepares to Present Promising Data at BIO International Convention
May 31, 2024
Via
AB Newswire
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
May 21, 2024
Via
AB Newswire
MAIA Biotechnology to Present at the BIO International Convention 2024
May 17, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
May 16, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
April 30, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
April 29, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces $1.00 Million Private Placement
April 23, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
April 05, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.